Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
58.83
+0.43 (0.74%)
At close: Mar 23, 2026, 4:00 PM EDT
60.00
+1.17 (1.99%)
After-hours: Mar 23, 2026, 4:59 PM EDT
Spruce Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
80.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
| Dec 31, 2023 | 10.09M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 57.95M |
| Kazia Therapeutics | 1.20M |
| Seres Therapeutics | 789.00K |
| MediciNova | 409.66K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 32.00K |
SPRB News
- 14 days ago - Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - Business Wire
- 14 days ago - Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer - Business Wire
- 21 days ago - Spruce Biosciences to Present at Upcoming Investor Conferences in March - Business Wire
- 4 weeks ago - Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 4 weeks ago - Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 6 weeks ago - Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 6 weeks ago - Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - Business Wire
- 7 weeks ago - Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - Business Wire